PROKIDNEY CORP. (PROK) AI Stock Price Forecast & Investment Analysis
Latest Analysis Date: August 22, 2025
PROKIDNEY CORP. (PROK) - Comprehensive Stock Analysis & Investment Research
Company Overview & Business Profile
PROKIDNEY CORP. (Stock Symbol: PROK)
is a leading company in the Life Sciences sector
, specifically operating within the Biological Products, (No Diagnostic Substances) industry.
The organization employs approximately 48 professionals worldwide
.
The company has established itself as
an emerging investment opportunity with substantial growth potential.
Financial Performance & Key Metrics Analysis
Market Capitalization: $-68 million - Classified as a
small-cap investment offering high growth potential.
Advanced AI Stock Prediction & Price Target Analysis
🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for PROKIDNEY CORP. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.
Market Position & Competitive Advantage Analysis
PROKIDNEY CORP. strategically competes in the highly dynamic
Biological Products, (No Diagnostic Substances) marketplace,
representing an emerging small-cap investment with substantial growth potential and market disruption capabilities
.
.
PROKIDNEY CORP. Stock Price Chart and Technical Analysis
Loading chart data...
Loading PROKIDNEY CORP. interactive price chart and technical analysis...
Deep dive into PROKIDNEY CORP.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.
Understanding Valuation Metrics
What these metrics mean: Valuation metrics help determine if PROKIDNEY CORP. stock is fairly priced compared to its earnings, assets, and market position.
How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.
For PROKIDNEY CORP.:
Market Cap$-68M
Understanding Profitability Metrics
What these metrics mean: These ratios measure how efficiently PROKIDNEY CORP. converts revenue into profit and generates returns for shareholders.
How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.
For PROKIDNEY CORP.:
Understanding Financial Health Metrics
What these metrics mean: These ratios assess PROKIDNEY CORP.'s ability to meet short-term obligations and manage debt levels effectively.
How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.
For PROKIDNEY CORP.:
Understanding Cash Flow Metrics
What these metrics mean: Cash flow metrics reveal PROKIDNEY CORP.'s ability to generate cash from operations and fund growth initiatives.
How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.
For PROKIDNEY CORP.:
Understanding Operational Efficiency Metrics
What these metrics mean: These ratios measure how effectively PROKIDNEY CORP. uses its assets and manages working capital.
How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.
For PROKIDNEY CORP.:
Understanding Financial Statement Data
What these metrics mean: Key figures from PROKIDNEY CORP.'s income statement and balance sheet showing absolute financial performance.
How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.
For PROKIDNEY CORP.:
Income Statement ($ Millions)
Operating Income$-6M
R&D Expense$110M
Balance Sheet Highlights ($ Millions)
Dividend & Shareholder Information
Shares Outstanding-28M
PROKIDNEY CORP. (PROK) Fundamental Analysis & Insider Trading Data
(Quarterly Financial Reports)
Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for PROKIDNEY CORP. stock analysis.
Loading fundamental data...
Loading PROKIDNEY CORP. comprehensive fundamental analysis and insider trading data...
ProKidney Corp., a late clinical-stage biotech company specializing in cell therapy for chronic kidney disease (CKD), announced that its CEO, Bruce Culleton, M.D., will present at the 43rd Annual ...
ProKidney Corp. Announces FDA Alignment on Accelerated Approval Pathway for Rilparencel in Chronic Kidney Disease and Diabetes July 15, 2025 — 07:42 am EDT Written by None for Quiver Quantitative -> ...
On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III (Nasdaq: DNAC).
The associated price target is $6.00. Justin Zelin’s Buy rating for ProKidney’s stock is majorly influenced by a series of factors that are promising for the company’s future.
WINSTON-SALEM, N.C., Nov. 13, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on ...
In a report released on January 5, Justin Zelin from BTIG maintained a Buy rating on ProKidney (PROK – Research Report), with a price target of $6.00. The company’s shares closed last Friday ...
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024 WINSTON-SALEM, N.C ...
The newly formed company is named ProKidney Corp. and its Class A ordinary shares will commence trading on the Nasdaq Capital Market (“Nasdaq”) under the symbol “PROK” on July 12, 2022.
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. ProKidney Corp. currently has a ...
ProKidney completed its previously announced business combination with SCS and commenced trading of the combined company’s Class A ordinary shares on the Nasdaq Capital Market under the ticker ...
PROKIDNEY CORP. Competitors & Peer Analysis - Life Sciences Sector
Comparative analysis of PROKIDNEY CORP. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.
How accurate are PROKIDNEY CORP. stock predictions?
Our AI model demonstrates 55% historical accuracy for PROK predictions, based on advanced machine learning algorithms trained on over 10 years of market data.
What factors influence PROKIDNEY CORP. stock price forecasts?
Based on our AI analysis, PROKIDNEY CORP. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.
How often are PROKIDNEY CORP. forecasts updated?
PROKIDNEY CORP. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.
Want More Advanced PROKIDNEY CORP. Analysis?
Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for PROKIDNEY CORP. stock.
